Company intelligence / Profile preview

Aqemia

Ownership: Private
Employees: ~60
Development stage: Preclinical

Overview

Aqemia is developing molecules for various indications, with the most advanced programs currently in in vivo optimization. The company plans to launch human clinical trials by the end of 2025[1]. Recently achieved a research milestone with Servier for an undruggable target in immuno-oncology[5].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Servier (pharmaceutical company)[5]

Beyond the preview

Go deeper on Aqemia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aqemia.

Explore the full profile